Is Omeros Corporation (OMER) a Buy, Sell, or Hold?
Omeros Corporation
NASDAQ:OMER
$10.5 USD
$0.49 (4.9%)
- Volume
- 1.39M
- Average Volume
- 1.76M
- Market Capitalization
- $759.94M
- P/E Ratio
- 8.08
- Dividend Yield
- 0.00%
- Price Target
- $33.00
- Year High
- $17.65
- Year Low
- $3.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.03
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gregory A. Demopulos |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | OMER |
| CUSIP | 682143102 |
| CIK | 0001285819 |
| Web | https://www.omeros.com |
| Phone | 206 676 5000 |
| Currency | USD |
| Employees | 175 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -4.90 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.03 |
| Quick Ratio | 3.03 |
| Cash Ratio | 0.03 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 76.82 |
| Cash Flow | -1.32 |
| Price / Cash Flow | -8.02 |
| Price / Book | -11.92 |
Price Target and Rating
| Average Stock Price Forecast | $33.00 |
| High Stock Price Forecast | $33.00 |
| Low Stock Price Forecast | $33.00 |
| Forecast Upside/Downside | -68.18% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0527 |
| Trailing P/E Ratio | 8.08 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-3.35M |
| Net Margin | 871.02% |
| Pretax Margin | 870.07% |
| Return on Equity | -54.39% |
| Return on Assets | 30.11% |
Financials Score
| AltmanZ Score | -1.35 |
| Piotroski Score | 6.00 |
| Working Capital | 120.91M |
| Total Assets | 286.17M |
| Ebit | 91.98M |
| Market Cap | 724.51M |
| Total Liabilities | 349.51M |
Poll Results
About Omeros Corporation (NASDAQ:OMER) Stock
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation ... for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
2026-07-14 17:03:41
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at newaction@pomlaw. com or 646-581-9980, ext. 7980. The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
2026-07-14 17:03:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Omeros Corporation Investigated by the Portnoy Law Firm
2026-07-13 14:16:00
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
2026-07-09 19:57:00
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
2026-07-08 17:21:25
Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease. Omeros is launching its first commercial product, Yartemlea, while maintaining a pipeline focused on rare diseases.
2026-07-08 09:34:00
LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ: OMER) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2026-07-07 17:47:00
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-06 19:57:00
LOS ANGELES--(BUSINESS WIRE)---- $OMER--OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm.
Frequently Asked Questions
-
What is the current Omeros Corporation (OMER) stock price?
-
Omeros Corporation(NASDAQ:OMER) stock price is $10.5 in the last trading session. During the trading session, OMER stock reached the peak price of $17.65 while $3.34 was the lowest point it dropped to. The percentage change in OMER stock occurred in the recent session was 4.9% while the dollar amount for the price change in OMER stock was $0.49.
-
OMER's industry and sector of operation?
-
The NASDAQ listed OMER is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OMER?
-
Catherine A. Melfi | Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems
George A. Gaitanaris | Chief Scientific Officer & Vice President of Science
Gregory A. Demopulos | Co-Founder, Chairman, Chief Executive Officer & President
David J. Borges | Vice President of Finance, Chief Accounting Officer & Treasurer
Peter Cancelmo | Vice President, General Counsel & Corporate Secretary -
How many employees does OMER have?
-
Number of OMER employees currently stands at 175. OMER operates from The Omeros Building, Seattle, WA 98119, US.
-
Link for OMER official website?
-
Official Website of OMER is: https://www.omeros.com
-
How do I contact OMER?
-
OMER could be contacted at phone #206 676 5000 and can also be accessed through its website. OMER operates from The Omeros Building, Seattle, WA 98119, US.
-
How many shares of OMER are traded daily?
-
The average number of OMER shares traded daily for last 3 months was 1.76M.
-
What is the market cap of OMER currently?
-
The market value of OMER currently stands at $759.94M with its latest stock price at $10.5